Drug Discovery
AI and Organoids Revolutionize Brain Disease Research
BrainStorm Therapeutics leverages AI and organoids to advance drug discovery for brain diseases, aiming to reduce clinical trial failures and accelerate treatment development.
Integrating AI and Experimental Feedback for Advanced Molecular Design
Explore how AI-driven generative chemistry, combined with experimental feedback, is transforming molecular design, drug discovery, and materials science, as outlined by NVIDIA.
Protai Leverages NVIDIA NIM and AlphaFold for Enhanced Protein Structure Prediction
Protai advances drug discovery by integrating NVIDIA NIM with AlphaFold and proteomics, optimizing protein structure predictions for precision medicine.
GenMol: A New Frontier in Molecular Generation for Drug Discovery
Explore GenMol, a generalist foundation model for molecular generation, and its advantages over SAFE-GPT in the realm of AI-driven drug discovery.
NVIDIA Introduces BioNeMo Blueprint to Revolutionize Protein Binder Design
NVIDIA unveils the BioNeMo Blueprint, a new AI-powered approach to accelerate protein binder design in drug discovery, leveraging GPU-accelerated microservices.
Mitsui & Co's Xeureka Utilizes NVIDIA AI for Secure Drug Discovery
Xeureka, a subsidiary of Mitsui & Co, leverages NVIDIA's AI platform to safely share healthcare data, enhancing drug discovery efforts through advanced confidential computing.
AI-Driven Drug Discovery Revolutionizes Treatment Development
AI's integration into drug discovery is transforming the development of treatments, reducing time and cost significantly, according to NVIDIA's blog.
NVIDIA's GPU Innovations Revolutionize Drug Discovery Simulations
NVIDIA's latest GPU optimization techniques, including CUDA Graphs and C++ coroutines, promise to accelerate pharmaceutical research by enhancing molecular dynamics simulations.
Yale, Moderna, and NVIDIA Harness Quantum Computing for Drug Discovery
Yale, Moderna, and NVIDIA explore quantum machine learning to enhance drug discovery. The collaboration focuses on GPU-accelerated simulation of quantum algorithms for predicting molecular properties.
Montai Therapeutics Leverages NVIDIA NIM for Multimodal AI Drug Discovery
Montai Therapeutics collaborates with NVIDIA to develop a multimodal AI platform for drug discovery using NVIDIA NIM microservices.